Willow Biosciences Inc.
WLLW.TO
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 546.90% | 288.13% | 77.91% | 89.21% | -13.99% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 546.90% | 288.13% | 77.91% | 89.21% | -13.99% |
| Cost of Revenue | -77.87% | -80.09% | -36.91% | -35.95% | -25.77% |
| Gross Profit | 237.29% | 189.22% | 66.57% | 53.24% | 27.70% |
| SG&A Expenses | -26.10% | -38.02% | -44.84% | -55.38% | -54.15% |
| Depreciation & Amortization | -40.83% | -25.50% | -28.73% | -12.15% | -23.88% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -21.38% | -31.27% | -39.46% | -42.77% | -39.49% |
| Operating Income | 70.22% | 59.07% | 51.40% | 49.98% | 40.99% |
| Income Before Tax | 61.90% | 53.11% | 52.01% | 50.27% | 36.86% |
| Income Tax Expenses | 450.00% | 342.86% | 1,206.45% | 120.22% | -104.94% |
| Earnings from Continuing Operations | 61.80% | 53.01% | 49.94% | 49.53% | 37.08% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 61.80% | 53.01% | 49.94% | 49.53% | 37.08% |
| EBIT | 70.22% | 59.07% | 51.40% | 49.98% | 40.99% |
| EBITDA | 74.44% | 62.99% | 53.03% | 51.38% | 40.48% |
| EPS Basic | 64.87% | 55.53% | 51.53% | 50.15% | 37.61% |
| Normalized Basic EPS | 65.59% | 54.83% | 52.36% | 49.77% | 34.90% |
| EPS Diluted | 64.87% | 55.53% | 51.53% | 50.15% | 37.61% |
| Normalized Diluted EPS | 65.59% | 54.83% | 52.36% | 49.77% | 34.90% |
| Average Basic Shares Outstanding | 11.53% | 8.00% | 4.54% | 1.24% | 0.72% |
| Average Diluted Shares Outstanding | 11.53% | 8.00% | 4.54% | 1.24% | 0.72% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |